State of the Art
Cannabis in cancer care
DI Abrams,
M Guzman,
Corresponding Author
DI Abrams
Hematology-Oncology, San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence: DI Abrams ([email protected]).Search for more papers by this authorM Guzman
Biochemistry and Molecular Biology, School of Biology, Complutense University, and Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
Search for more papers by this author
DI Abrams,
M Guzman,
Corresponding Author
DI Abrams
Hematology-Oncology, San Francisco General Hospital, Department of Medicine, University of California San Francisco, San Francisco, California, USA
Correspondence: DI Abrams ([email protected]).Search for more papers by this authorM Guzman
Biochemistry and Molecular Biology, School of Biology, Complutense University, and Centro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
Search for more papers by this authorAbstract
Cannabis has been used in medicine for thousands of years prior to achieving its current illicit substance status. Cannabinoids, the active components of Cannabis sativa, mimic the effects of the endogenous cannabinoids (endocannabinoids), activating specific cannabinoid receptors, particularly CB1 found predominantly in the central nervous system and CB2 found predominantly in cells involved with immune function. Delta-9-tetrahydrocannabinol, the main bioactive cannabinoid in the plant, has been available as a prescription medication approved for treatment of cancer chemotherapy-induced nausea and vomiting and anorexia associated with the AIDS wasting syndrome. Cannabinoids may be of benefit in the treatment of cancer-related pain, possibly synergistic with opioid analgesics. Cannabinoids have been shown to be of benefit in the treatment of HIV-related peripheral neuropathy, suggesting that they may be worthy of study in patients with other neuropathic symptoms. Cannabinoids have a favorable drug safety profile, but their medical use is predominantly limited by their psychoactive effects and their limited bioavailability.
References
- 1 R.G. Pertwee (ed). Handbook of Cannabis (Oxford University Press, Oxford, UK, 2014).
10.1093/acprof:oso/9780199662685.001.0001 Google Scholar
- 2 Sallen, S.E., Zinberg, N.E. & Frei, E. Antiemetic effect of delta-9-THC in patients receiving cancer chemotherapy. N. Engl. J. Med. 293, 795–797 (1975).
- 3 Gorter, R., Seefried, M. & Volberding, P. Dronabinol effects on weight in patients with HIV infection. AIDS. 6, 127 (1992).
- 4 Beal, J.E. et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 10, 89–97 (1995).
- 5 Russo, E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344–1364 (2011).
- 6 Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397–411 (2009).
- 7 Miller, L.K. & Devi, L.A. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol. Rev. 63, 461–470 (2011).
- 8 Borgelt, L.M., Franson, K.L., Nussbaum, A.M. & Wang, G.S. The pharmacologoic and clinical effects of medical cannabis. Pharamcotherapy. 3, 195–209 (2013).
- 9 J.E. Joy, S.J. Watson & J.A. Benson (eds). Marijuana and Medicine: Assessing the Science Base (National Academy Press, Washington, DC, 1999).
- 10 Karschner, E.L. et al. Plasma cannabinoid pharmacokinetics following controlled oral Delta-9tetrahydrocannabinol and oromucosal cannabis extract administration. Clin. Chem. 57, 66–75 (2011).
- 11 Engels, F.K. et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. 12, 291–300 (2007).
- 12 Sutton, I.R. & Daeninck, P. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J. Support. Oncol. 4, 531–535 (2006).
- 13 Tramer, M.R. et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ. 323, 16–21 (2001).
- 14 Ben Amar, M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 105, 1–25 (2006).
- 15 Walsh, D., Nelson, K.A. & Mahmoud, F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 11, 137–143 (2003).
- 16 Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br. J. Clin. Pharmacol. 70, 656–663 (2010).
- 17 Brisbois, T.D. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann. Oncol. 22, 2086–2093 (2011).
- 18 Mechoulam, R., Berry, E.M., Avraham, Y., DiMarzo, V. & Fride, E. Endocannabinoids, feeding and suckling – from our perspective. Int. J. Obes. (Lond). Suppl.1, S24–S28 (2006).
- 19 Christensen, R., Kristensen, P.K., Bartals, E.M., Bliddal, H. & Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 370, 1706–1713 (2007).
- 20 Le Strat, Y. & Le Foll, B. Obesity and cannabis use: results from 2 representative national surveys. Am. J. Epidemiol. 174, 929–933 (2011).
- 21 Penner, E.A., Buettner, H. & Mittleman, M.A. The impact of marijuana use on glucose, insulin, and insulin resistance. Am. J. Med. 126, 583–589 (2013).
- 22 Fine, P.G. & Rosenfeld, M.J. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med. J. 4, eooXX (2013).
10.5041/RMMJ.10129 Google Scholar
- 23 Facci, L. et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U. S. A. 92, 3376–3380 (1995).
- 24 Ibrahim, M.M. et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U. S. A. 102, 3093–3098 (2005).
- 25 Elikottil, J., Gupta, P. & Gupta, K. The analgesic potential of cannabinoids. J Opioid Manage. 5, 341–357 (2009).
- 26 Noyes, R., Brunk, S., Baram, D. & Canter, A. Analgesic effect of delta-9-tetrahydrocannabinol. J. Clin. Pharmacol. 15, 139–143 (1975).
- 27 Noyes, R., Brunk, S., Avery, D. & Canter, A. The analgesic properties of delta-9-tertrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18, 84–89 (1975).
- 28 Noyes, R. & Baram, D. Cannabis analgesia. Compr. Psychiatry. 15, 531 (1974).
- 29 Johnson, J.R. et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom. Manage. 39, 167–178 (2010).
- 30 Herzberg, U., Eliav, E., Bennett, G.J. & Kopin, I.J. The analgesic effect of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221, 157–160 (1997).
- 31 Abrams, D.I. et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized, placebo-controlled trial. Neurology. 68, 515–521 (2007).
- 32 Wilsey, B. et al. A randomized, placebo-controlled crossover trial of cannabis cigarettes in neuropathic pain. J. Pain. 9, 506–521 (2008).
- 33 Ellis, R.J. et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychoparmacology. 34, 672–680 (2009).
- 34 Wilsey, B. et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J. Pain. 14, 136–148 (2013).
- 35 Svendsen, K.B., Jensen, T.S. & Back, FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 329, 253–260 (2004).
- 36 Rog, D.J., Nurmikko, T.J., Fride, T. & Young, C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 65, 812–819 (2005).
- 37 Lynch, M.E., Cesar-Rittenberg, P. & Hohmann, A.G. A double-blind, placebo-controlled, cross-over pilot with extension using an oral mucosal cannabinoid-extract for treatment of chemotherapy-induced neuropathic pain. J. Pain Symptom. Manage. 47, 166–173 (2014).
- 38 Ward, S.J., McAllister, S.D., Neelakantan, H. & Walker, E.A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br. J. Pharmacol. 171, 636–645 (2014).
- 39 Cichewicz, D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74, 1317–1324 (2004).
- 40 Abrams, D.I. et al. Cannabinoid:opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844–851 (2011).
- 41 Russo, E.B., Guy, G.W. & Robson, P.J. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem. Biodivers. 4, 1729–1743 (2007).
- 42 Ware, M.A. et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 182, E694–701 (2010).
- 43 Bar-Sela, G. et al. The medical necessity for medicinal cannabis: prospective, observational study evaluating treatment in cancer patients on supportive or palliative care. Evid. Based Complement. Altern. Med. 2013, 510392 (2013).
- 44 Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer. 3, 745–755 (2003).
- 45 Velasco, G., Sánchez, C. & Guzmán, M. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer. 12, 436–444 (2012).
- 46 Bowles, D.W., O'Bryant, C.L., Camidge, R. & Jimeno, A. The intersection between cannabis and cancer in the United States. Crit. Rev. Oncol. Hematol. 83, 1–10 (2012).
- 47 Munson, A.E., Harris, L.S., Friedman, M.A., Dewey, W.L. & Carchman, R.D. Antineoplastic activity of cannabinoids. JNCI. 55, 597–602 (1975).
- 48 Bifulco, M., Laezza, C., Pisanti, S. & Gazzerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br. J. Pharmacol. 148, 123–135 (2006).
- 49 De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 95, 8375–8380 (1998).
- 50 McKallip, R.J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 100, 627–634 (2002).
- 51 Patsos, H.A., Hicks, D.J., Greenhough, A., Williams, A.C. & Paraskeva, C. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem. Soc. Trans. 33, 712–714 (2005).
- 52 Sarfaraz, S., Afaq, F., Adhami, V.M. & Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65, 1635–1641 (2005).
- 53 McAllister, S.D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured glioblastoma multiforme cells. J. Neurooncol. 74, 31–40 (2005).
- 54 Torres, S. et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10, 90–103 (2011).
- 55 Marcu, J.P. et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 9, 180–189 (2010).
- 56 Guzman, M. et al. A pilot study of Delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer. 95, 1–7 (2006).
- 57 U.S. Department of Health and Human Services NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1-Trans-Delta9-Tetrahydrocannabinol in F344/N Rats and B6C3F1 Mice (Gavage Studies). TR-446, November 1996. http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr446.pdf
- 58 Callaghan, R.C., Allebeck, P. & Sidorchuk, A. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control. 24, 1811–1820 (2013).
- 59 Sidney, S., Quesenberry, C.P., Friedman, G.D. & Tekewa, I.S. Marijuana use and cancer incidence (California, USA). Cancer Causes Control. 8, 722–728 (1997).
- 60 Hashibe, M. et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Epidemiol. Biomarkers Prev. 15, 1829–1834 (2006).
- 61 Mehra, R., Moore, B.A., Crothers, K., Tetrault, J. & Fiellin, D.A. The association between marijuana smoking and lung cancer: a systematic review. Arch. Intern. Med. 166, 1359–1367 (2006).
- 62 Zhang, L.R. et al. Cannabis smoking and lung cancer risk: pooled analysis in ther International Lung Cancer Consortium. Int. J. Cancer. 136, 894–903 (2015).
- 63 Daling, J.R. et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer. 115, 1215–1223 (2009).
- 64 Trabert, B. et al. Marijuana use and testicular germ cell tumors. Cancer. 117, 848–853 (2011).
- 65 Lacson, J.C. et al. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 118, 5374–5383 (2012).
- 66 Thomas, A.A. et al. Association between cannabis use and the risk of bladder cancer: results from the California Men's Health Study. Urology. 85, 388–393 (2015).
- 67 Huang, Y.H. et al. An epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol. Biomarkers Prev. 24, 15–31 (2015).
- 68 Volkow, N.D., Baler, R.D., Compton, W.M. & Weiss, S.R.B. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219–2227 (2014).
- 69 Carter, G.T., Weydt, P., Kyashna-Tocha, M. & Abrams, D.I. Medicinal cannabis: rational guidelines for dosing. IDrugs. 7, 464–470 (2004).
- 70 Bostwick, J.M., Reisfield, G.M. & DuPont, R.L. Medicinal use of marijuana. N. Engl. J. Med. 368, 866–868 (2013).
- 71 Adler, J.N. & Colbert, J.A. Medicinal use of marijuana – polling results. N. Engl. J. Med. 368, e30 (2013).
